Rocket Doctor AI Announces Strong Q3 2026 Patient Visit Growth and Expects Record Quarterly Revenue
Certain U.S. revenues are recognized only when cash arrives, so patient visit growth does not immediately translate into reported revenue.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rocket Doctor AI (AIRDF) completed 53,348 patient visits across the U.S. and Canada in the third quarter of 2026. U.S. visits increased 56% quarter-over-quarter to 6,101 from 3,911, while Canadian visits rose 24% year-over-year to 47,247 from 37,960. U.S. clinical hours increased 33% to 2,634 from 1,987.5 in Q2 2026.
The company expects record Q3 2026 revenue as cash collections catch up with patient activity. Certain U.S. revenues are recognized on a cash basis, creating a lag between visits and revenue recognition. Reimbursement for out-of-network visits is generally not expected, and any recoveries are recognized only upon cash receipt. The U.S. network includes more than 20 in-network payer agreements covering commercial insurance, Medicare Advantage and Medicaid. Management plans to continue evaluating coverage and payer relationships to convert out-of-network patients and physicians to in-network status.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointU.S. completed visits rose 56% quarter-over-quarter to 6,101 in Q3 2026, from 3,911.
- Moderate pointCanadian completed visits increased 24% year-over-year to 47,247 in Q3 2026, from 37,960.
- Moderate pointU.S. clinical hours increased 33% to 2,634 in Q3 2026, from 1,987.5 in Q2 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Quarterly revenue is expected by the company to reach a record in Q3 2026.
- Minor pointU.S. network comprises over 20 in-network payer agreements across commercial insurance, Medicare Advantage and Medicaid.
- Minor point. Forward-looking: it has not happened yet and may not happen.Management plans continued coverage and payer reviews to convert out-of-network patients and physicians to in-network status.
Negative
- Moderate pointCertain U.S. revenues face a recognition lag because they are recorded on a cash basis.
- Moderate pointOut-of-network visit reimbursement is generally not expected; recoveries are recognized only upon actual cash receipt.
- Minor pointIn-network reimbursement eligibility requires both patient and treating physician enrollment with the applicable insurer, Medicare or Medicaid.
Details
News Market Reaction – AIRDF
On Oct 15, the day this news came out, AIRDF closed 7.10% above the previous close.
Data tracked by StockTitan Argus for the Oct 15 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Rocket Doctor AI completed 53,348 patient visits across the U.S. and Canada in Q3 2026, including 6,101 U.S. visits and 47,247 Canadian visits.
- U.S. completed patient visits increased
56% quarter-over-quarter, from 3,911 in Q2 2026 to 6,101 in Q3 2026. - Canadian completed patient visits grew
24% year-over-year to 47,247, compared with 37,960 in Q3 2025. - Company expects record quarterly revenue in Q3 2026 as patient visits continue to increase and cash collections catch up.
Vancouver, BC, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) ("Rocket Doctor AI" or the "Company"), a physician-built, AI-powered healthcare technology company focused on empowering doctors and expanding access to high-quality care, is pleased to announce strong patient visit growth for the quarter ended September 30, 2026, and expects to report record quarterly revenue for Q3 2026.
The Company completed 53,348 patient visits across its U.S. and Canadian operations during the third quarter. U.S. visits rose
“Our Q3 performance highlights the accelerating demand for Rocket Doctor AI’s physician-built, AI-powered platform across North America,” said Dr. Essam Hamza, CEO of Rocket Doctor AI. “Surpassing 50,000 total patient visits across Canada and the U.S. in a single quarter is a remarkable operational milestone. The
While U.S. patient volumes grew significantly in Q2, the associated revenue growth was not immediately reflected in our reported results because of the lag between patient visits, claims processing and cash collections. With U.S. patient visits increasing a further
The increase in completed US visits and the number of U.S. clinical hours are important leading indicators to demonstrate the growth of Rocket Doctor AI’s operational and financial performance. As a result, the Company expects to report record quarterly revenue for Q3 2026
Q3 2026 Operational Highlights:
- U.S. patient visits: 6,101 completed visits, an increase of
56% from 3,911 in Q2 2026. - U.S. clinical hours: 2,634 hours, an increase of
33% from 1,987.5 in Q2 2026. - Canadian patient visits: 47,247 completed visits, an increase of
24% from 37,960 in Q3 2025.
The increase in U.S. visits reflects the Company’s continued execution of its multi-payer strategy across key state markets. By continuing to build upon our network of over 20 in-network payer agreements spanning commercial, Medicare Advantage, and Medicaid verticals, the Company is driving scalable, quarter-over-quarter operational growth while laying a durable foundation to expand healthcare access and long-term revenue visibility.
Revenue Recognition and Timing Lag
As detailed in the Company's News Release dated September 1, 2026, it should be noted that because the Company currently recognizes certain U.S. revenues on a cash basis, there is a timing lag between the significant increase in patient visits and the corresponding recognition of revenue.
Further, as described in the Company’s interim Q2 Management’s Discussion and Analysis (“MD&A”), available under its profile on SEDAR+ at www.sedarplus.ca, the following should be noted:
(i) In connection with its U.S. operations, the Company distinguishes between in-network and out-of-network patients when determining reimbursement eligibility for patient visits conducted through its platform. For in-network patients, both the patient and the treating physician must be enrolled with the applicable insurance provider, Medicare, or Medicaid for a reimbursement claim to be eligible for payment. For out-of-network patients, the Company has made a strategic decision to permit access to its platform to drive adoption and expand its user base during this early stage of its U.S. market development.
(ii) While reimbursement for out-of-network visits is generally not expected, the Company will nonetheless submit claims on behalf of these visits where possible, as there remains a possibility that certain claims may be approved at the discretion of the payor.
(iii) Consistent with the Company's overall revenue recognition policy for its U.S. operations, any amounts recovered in respect of out-of-network claims will only be recognized as revenue upon actual cash receipt, reflecting the heightened uncertainty of collection associated with these visits. Management will continue to evaluate its network coverage and payor relationships with a view to converting out-of-network patients and physicians to in-network status over time, which is expected to improve reimbursement rates and provide greater revenue visibility going forward.
About Rocket Doctor AI Inc.
Rocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed to make high-quality healthcare accessible throughout the entire patient journey. A cornerstone of the company’s proprietary technology is the Global Library of Medicine (GLM), a clinically validated decision support system developed with input from hundreds of physicians worldwide.
Alongside the GLM is Rocket Doctor Inc, and its AI-powered digital health platform and marketplace. Having helped empower over 350 MDs to provide care to more than 800,000 patient visits, our proprietary technology software and systems enable doctors to independently launch and manage their own virtual or hybrid in-person practices - improving efficiency, restoring autonomy to MDs, and expanding patient access to care.
By reducing administrative burdens and ensuring greater consistency in care, our technology creates more time for meaningful physician-patient interactions. We are committed to reaching underserved, rural, and remote communities in Canada who often lack access to family doctors and supporting patients on Medicaid and Medicare in the United States. With advanced AI, large language models, and connected medical devices, Rocket Doctor AI is redefining modern healthcare - making it more scalable, equitable, and patient-centered.
To learn more about Rocket Doctor AI Inc’s products and services, contact: www.rocketdoctor.ai or email: info@rocketdoctor.ai
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO, Rocket Doctor AI essam.hamza@rocketdoctor.ai
Dr. Bill Cherniak, CEO, Rocket Doctor Inc. bill@rocketdoctor.io
For media inquiries, contact: media@rocketdoctor.ai
Call: +1 (778) 819 8321
Cautionary Statements
This news release contains forward-looking statements relating to the future operations of Rocket Doctor AI Inc. and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Company Town Hall Company's expectation of record quarterly revenues for Q3 2026, the Company's growth strategy for and continued expansion in the United States and Canada, the Company's multi-payer strategy and expansion of in-network payor coverage, the Company's expectation to convert out-of-network patients and physicians to in-network status over time, and future plans and objectives of Rocket Doctor AI Inc., are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Rocket Doctor AI Inc.'s expectations include other risks detailed from time to time in the filings made by Rocket Doctor AI Inc. with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Rocket Doctor AI Inc. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Rocket Doctor AI Inc. will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many patient visits did Rocket Doctor AI complete in Q3 2026?
Rocket Doctor AI completed 53,348 patient visits across the U.S. and Canada in Q3 2026. That included 6,101 U.S. visits, up 56% from Q2 2026, and 47,247 Canadian visits, up 24% from Q3 2025.
What must happen for Rocket Doctor AI's in-network U.S. visits to qualify for reimbursement?
Both the patient and treating physician must be enrolled with the applicable insurance provider, Medicare or Medicaid for an in-network reimbursement claim to be eligible for payment.
Why does Rocket Doctor AI allow out-of-network patients to use its U.S. platform?
The company says it allows out-of-network access to drive adoption and expand its user base during early U.S. market development. It submits claims where possible, although reimbursement is generally not expected and approval remains at the payer's discretion.